Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem have announced a collaboration agreement to accelerate early-stage drug discovery. X-Chem will provide access to its DNA-encoded library (DEL) technology, including DELflex and HITMiner, which can screen billions of DNA-tagged compounds simultaneously. This partnership aims to combine X-Chem's DEL technology with Evotec's screening platforms to identify potential drug candidates more efficiently for innovative biological targets.
The collaboration highlights the importance of partnerships in addressing the complexity of drug discovery. Both companies' CEOs expressed enthusiasm about the potential of this collaboration to enhance drug discovery processes and tackle challenging biological targets.
Evotec SE (Borsa di Francoforte: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) e X-Chem hanno annunciato un accordo di collaborazione per accelerare la scoperta di farmaci nelle fasi iniziali. X-Chem fornirà accesso alla sua tecnologia delle librerie codificate in DNA (DEL), tra cui DELflex e HITMiner, in grado di screeningare miliardi di composti taggati con DNA simultaneamente. Questa partnership ha l'obiettivo di combinare la tecnologia DEL di X-Chem con le piattaforme di screening di Evotec per identificare in modo più efficiente i potenziali candidati farmaceutici per innovativi bersagli biologici.
La collaborazione sottolinea l'importanza delle alleanze nell'affrontare la complessità della scoperta di farmaci. I CEO di entrambe le aziende hanno espresso entusiasmo riguardo al potenziale di questa collaborazione per migliorare i processi di scoperta di farmaci e affrontare sfide biologiche complesse.
Evotec SE (Bolsa de Frankfurt: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) y X-Chem han anunciado un acuerdo de colaboración para acelerar el descubrimiento de medicamentos en las primeras etapas. X-Chem proporcionará acceso a su tecnología de bibliotecas codificadas por ADN (DEL), que incluye DELflex y HITMiner, las cuales pueden examinar miles de millones de compuestos etiquetados con ADN simultáneamente. Esta asociación tiene como objetivo combinar la tecnología DEL de X-Chem con las plataformas de detección de Evotec para identificar candidatos a medicamentos de manera más eficiente para objetivos biológicos innovadores.
La colaboración destaca la importancia de las asociaciones para abordar la complejidad del descubrimiento de medicamentos. Los directores ejecutivos de ambas compañías expresaron su entusiasmo por el potencial de esta colaboración para mejorar los procesos de descubrimiento de medicamentos y abordar objetivos biológicos desafiantes.
Evotec SE (프랑크푸르트 증권 거래소: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO)와 X-Chem은 초기 약물 발견을 가속화하기 위한 협력 계약을 발표했습니다. X-Chem은 DELflex와 HITMiner를 포함한 DNA 인코딩 라이브러리(DEL) 기술에 대한 접근을 제공하며, 이는 수십억 개의 DNA 태그가 있는 화합물을 동시에 스크리닝할 수 있습니다. 이 파트너십은 X-Chem의 DEL 기술과 Evotec의 스크리닝 플랫폼을 결합하여 혁신적인 생물학적 표적에 대해 잠재적인 약물 후보를 더 효율적으로 식별하는 것을 목표로 하고 있습니다.
이번 협력은 약물 발견의 복잡성에 대응하기 위한 파트너십의 중요성을 강조합니다. 두 회사의 CEO들은 이 협력이 약물 발견 프로세스를 향상시키고 도전적인 생물학적 표적을 다루는 잠재력에 대해 열정을 표명했습니다.
Evotec SE (Bourse de Francfort : EVT, MDAX/TecDAX, ISIN : DE0005664809 ; NASDAQ : EVO) et X-Chem ont annoncé un accord de collaboration pour accélérer la découverte de médicaments à un stade précoce. X-Chem fournira l'accès à sa technologie de bibliothèque codée par ADN (DEL), y compris DELflex et HITMiner, qui peut évaluer des milliards de composés marqués par ADN simultanément. Ce partenariat vise à combiner la technologie DEL de X-Chem avec les plateformes de dépistage d'Evotec afin d'identifier plus efficacement de potentiels candidats médicaments pour des cibles biologiques innovantes.
La collaboration souligne l'importance des partenariats pour faire face à la complexité de la découverte de médicaments. Les PDG des deux entreprises ont exprimé leur enthousiasme quant au potentiel de cette collaboration pour améliorer les processus de découverte de médicaments et s'attaquer à des cibles biologiques difficiles.
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) und X-Chem haben eine Kooperationsvereinbarung bekannt gegeben, um die Frühphasen- Arzneimittelentdeckung zu beschleunigen. X-Chem wird Zugang zu seiner DNA-verschlüsselten Bibliotheks (DEL) Technologie gewähren, darunter DELflex und HITMiner, die in der Lage sind, Milliarden von DNA-markierten Verbindungen simultan zu screenen. Dieses Partnerschaft zielt darauf ab, die DEL-Technologie von X-Chem mit den Screening-Plattformen von Evotec zu kombinieren, um potenzielle Arzneimittelkandidaten effizienter für innovative biologische Ziele zu identifizieren.
Die Zusammenarbeit hebt die Bedeutung von Partnerschaften hervor, um die Komplexität der Arzneimittelentdeckung zu bewältigen. Die CEOs beider Unternehmen äußerten sich begeistert über das Potenzial dieser Zusammenarbeit zur Verbesserung der Arzneimittelentdeckungsprozesse und zur Bewältigung herausfordernder biologischer Ziele.
- Partnership with X-Chem provides Evotec access to advanced DNA-encoded library (DEL) technology
- Collaboration aims to accelerate early-stage drug discovery processes
- Access to X-Chem's DELflex and HITMiner solutions for more efficient compound screening
- None.
This collaboration between Evotec and X-Chem marks a significant advancement in early-stage drug discovery. X-Chem's DNA-encoded library (DEL) technology, capable of screening billions of compounds simultaneously, combined with Evotec's established screening platforms, creates a powerful synergy in the drug discovery process.
The partnership's potential to accelerate hit identification and optimize starting points for drug development could lead to reduced timelines and costs in bringing new therapies to market. This is particularly important for addressing complex or novel biological targets that have traditionally been challenging to drug.
For investors, this collaboration signals Evotec's commitment to innovation and could potentially enhance its competitive edge in the contract research organization (CRO) space. However, it's important to note that early-stage drug discovery successes don't always translate to marketable drugs and the long-term financial impact remains to be seen.
This partnership highlights a growing trend in the pharmaceutical industry towards collaborative, technology-driven drug discovery. By combining X-Chem's DEL technology with Evotec's screening capabilities, both companies are positioning themselves at the forefront of innovation in hit identification and lead optimization.
The inclusion of X-Chem's HITMiner machine learning solution is particularly noteworthy, as it represents the increasing role of AI and data analytics in drug discovery. This could potentially reduce the risk and cost associated with early-stage drug development, a critical factor in an industry where R&D productivity has been declining.
For Evotec, this collaboration could enhance its service offerings to clients, potentially leading to increased business opportunities. However, investors should be aware that the impact on revenue may not be immediate, as drug discovery is a long-term process with uncertain outcomes.
This collaboration taps into the growing market for AI-driven drug discovery, which is projected to reach
Investors should note that while this collaboration doesn't guarantee immediate financial returns, it strengthens Evotec's value proposition in a market that increasingly demands innovative solutions. The company's ability to offer cutting-edge DEL technology could attract more high-value partnerships and contracts.
However, the impact on stock performance may be gradual rather than immediate. The true value of this collaboration will likely be realized over time as it contributes to Evotec's pipeline of drug discovery projects and potentially leads to successful drug candidates for its clients.
X-Chem’s DEL technology streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, identifying potential start points with high efficiency and precision.
In partnership with Evotec’s screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets.
“Partnerships to access best-in-class platforms are the way forward to address the complexity in drug discovery,” said Karen Lackey, CEO of X-Chem. “This collaboration highlights our commitment to partner with leading research organizations, like Evotec, to make DEL screening services more accessible.”
“We are pleased to collaborate with X-Chem and to leverage their leading DEL platform and capabilities,” said Craig Johnstone, chief operating officer of Evotec. “X-Chem’s expertise in DEL, combined with their advanced data-mining solutions, provides us with access to an additional tool to tackle innovative and difficult biological targets.”
About X-Chem
X-Chem, Inc. is a leader in small molecule discovery science, providing pharmaceutical and biotechnology companies with a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to rapidly screen billions of diverse drug-like molecules to discover novel small molecule leads against challenging, high-value therapeutic targets. In house hit-to-lead and lead optimization services driven by AI and physics-based modeling enable clients to progress their compounds directly in-house from hit all the way through to candidate nomination. Our well-proven expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery in a deeply integrated technology-driven platform.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905884203/en/
Holli Kroeker
SCORR Marketing
(308) 338-2358
pr@scorrmarketing.com
Source: X-Chem
FAQ
What is the purpose of the collaboration between Evotec (EVO) and X-Chem?
What technology is X-Chem providing to Evotec (EVO) in this collaboration?
How does X-Chem's DEL technology benefit drug discovery for Evotec (EVO)?
When was the collaboration between Evotec (EVO) and X-Chem announced?
